Site-Specific Dual Antibody Conjugation via Engineered Cysteine and Selenocysteine Residues.


Site-specific conjugation technologies enable the production of homogeneous antibody-drug conjugates (ADCs) with improved therapeutic indices compared to conventional ADCs. However, current site-specific conjugation methods can only attach one type of drug to a single antibody. Given the emergence of acquired resistance to current ADCs, arming single… (More)
DOI: 10.1021/acs.bioconjchem.5b00244

5 Figures and Tables


  • Presentations referencing similar topics